MYC and cancer: However, in contrast to its mechanism of action in these cancer types, we previously found that inhibition of lung adenocarcinoma (LAC) by the BET inhibitor JQ1 is c-MYC independent, with the oncogenic transcription factor FOSL1 functioning as the likely downstream target in this tumor type22.